entertainment -WSS

entertainment

author：comprehensive 2025-09-29 18:16:55 - browse：762

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

Roche said Monday it was buying Telavant Holdings for $7.1 billion upfront, picking up a promising experimental therapy for inflammatory bowel diseases.

Telavant is owned by Roivant Sciences, with Pfizer holding a minority stake. The deal will allow Roche to develop the therapy, called RVT-3101, and, pending approval, sell it in the United States and Japan. Pfizer holds the commercial rights in other parts of the world.

The “Roi” in Roivant stands for “return on investment” and with this deal, the biotech, founded by Republican presidential candidate Vivek Ramaswamy but now run by CEO Matt Gline, certainly delivered. Last December, it essentially acquired RVT-3101 from Pfizer for $45 million and a commitment to invest in the drug’s development. Less than a year later, Roivant flipped the drug to Roche for at least $7.1 billion.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： A disappointing year of Humira biosimilars

knowledge

explore

WSS

KalVista pill reduced swelling 'attacks' caused by genetic disease

Hundreds died while taking an arthritis drug, but nobody alerted patients

Pancreatic cancer is often deadly, but new discoveries are raising hope

Gut bacteria may contribute to kidney autoimmunity, study finds

Florida Supreme Court upholds state's abortion ban

Robert F. Kennedy is pitching centrism on health, even on abortion

focus

entertainment

explore

Wildfire smoke exposes gaps in outdoor worker protections

Four alarming medical procedures we’re glad history forgot

Walensky prepares to leave CDC — and Congress — behind

What we’ve learned from the Aduhelm mess

In Memoriam: Notable people who died in 2023

Mass General Brigham physicians react to latest merger step

Wildfire smoke exposes gaps in outdoor worker protections

KalVista pill reduced swelling 'attacks' caused by genetic disease

Psychedelics group wrestles with new pharma identity

Biogen Alzheimer’s drug launch off to slow start

focus

Medical mystery: When a cough is not just a cough

PhRMA lawsuit over Medicare drug price negotiation tossed

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

First Opinion on colorectal cancer screening: letter and response

Doctors' information doesn't help them choose wisely when sick

Harvard scientists, with Google, unveil the most detailed brain map ever

hotspot

knowledge

explore

leisure time